Evidence map›Paper›PMID 35968320›Full record

ArticleAmerican journal of cancer research2022

A novel 8-gene panel for prediction of early biochemical recurrence in patients with prostate cancer after radical prostatectomy.

Jinan Guo, Chenhui Zhao, Xinzhou Zhang, Zhong Wan, Tingting Chen, Jiashun Miao, Jinping Cai, Wenchuan Xie, Hao Chen, Mengli Huang and 3 more

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in American journal of cancer research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 2 countries.

Jinan GuoDepartment of Urology, The Second Clinical Medical College of Jinan University, Shenzhen People's Hospital, The First Affiliated Hospital of South University of Science and Technology of China Shenzhen, China.
Chenhui ZhaoRuijin Hospital Lu Wan Branch, Shanghai Jiao Tong University School of Medicine Shanghai, China.
Xinzhou ZhangDepartment of Nephrology, Shenzhen key Laboratory of Kindey Diseases, The Second Clinical Medical College of Jinan University, Shenzhen People's Hospital, The First Affiliated Hospital of South University of Science and Technology of China Shenzhen, China.
Zhong WanShuguang Hospital, Shanghai University of Traditional Chinese Medicine Shanghai, China.
Tingting Chen3D Medicines, Inc Shanghai, China.
Jiashun Miao3D Medicines, Inc Shanghai, China.
Jinping Cai3D Medicines, Inc Shanghai, China.
Wenchuan Xie3D Medicines, Inc Shanghai, China.
Hao Chen3D Medicines, Inc Shanghai, China.
Mengli Huang3D Medicines, Inc Shanghai, China.
Xiaochen Zhao3D Medicines, Inc Shanghai, China.
Wei WeiDepartment of Urology, Hwa Mei Hospital, University of Chinese Academy of Sciences Ningbo, China.
Qi ShenDepartment of Hematology, The Second Clinical Medical College of Jinan University, Shenzhen People's Hospital, The First Affiliated Hospital of South University of Science and Technology of China Shenzhen, China.
Western Digital (China) · CNShenzhen Second People's Hospital · CNCenter for Special Minimally Invasive and Robotic Surgery · USNingbo No. 2 Hospital · CNRuijin Hospital · CNShanghai University of Traditional Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Approximately 25% of prostate cancer (PCa) cases experience biochemical recurrence (BCR) following radical prostatectomy (RP). The patients with BCR, especially with BCR ≤2 year after RP (early BCR), are more likely to develop clinical metastasis and castration resistance. Now decision-making regarding BCR after RP relies solely on clinical parameters. We thus attempted to establish an early BCR-risk prediction model by combining a molecular signature with clinicopathological features for guiding clinical decision-making. In this study, an 8-gene signature was derived, and these eight genes were

Indexed as

biochemical recurrencebiochemical recurrence-free survivalgene signatureProstate cancerrisk stratification

Identifiers

PMID35968320
PMCPMC9360249
OpenAlexW4299530345

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.